Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients

被引:78
作者
Kristensen, VN [1 ]
Andersen, TI
Erikstein, B
Geitvik, G
Skovlund, E
Nesland, JM
Borresen-Dale, AL
机构
[1] Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Inst Canc Res, Dept Pathol, N-0310 Oslo, Norway
[3] Ulleval Univ Hosp, Dept Med Genet, Oslo, Norway
[4] Univ Oslo, Sect Med Stat, N-0316 Oslo, Norway
来源
PHARMACOGENETICS | 1998年 / 8卷 / 05期
关键词
GSTM1; GSTT1; GSTP1; loss of heterozygosity; TP53; breast cancer risk;
D O I
10.1097/00008571-199810000-00009
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Glutathione S-transferases are involved in the conjugation of a number of human carcinogens. The frequencies of the deletion alleles coding for GSTM1, and GSTT1, related to deficient conjugation of xenobiotics, as well as a recently reported variant in the exon 5 of GSTP1 were investigated in this study. A multiplex polymerase chain reaction based method for a rapid and high throughput genotype analysis of all three GSTM1, GSTT1 and GSTP1 genes fn a single tube was developed, Leukocyte DNA from two hundred and thirty-nine (n = 239) breast cancer patients were genotyped. Tumors from a subset of these breast cancer patients (n = 131) hare previously been investigated for mutations in the TP53 gene, levels of p53 protein accumulation and loss of heterozygosity at several loci on chromosome 17, When genetic alterations in the tumors were analyzed with respect to glutathione S-transferase genotypes, a significantly higher proportion of the patients with a G allele (GG + AG) of the GSTP1 had loss of heterozygosity at the TP53 gene locus mapping to 17p, compared with non-G allele carriers (74% versus 29%) (P = 0.018). The patients carrying the G allele of GSTP1 also had more frequently mutations in the TP53 gene in their tumor (38%), compared with patients with the AA genotype (21%) (P = 0.055). G allele carriers had predominantly deletion or transversion mutations in the TP53 gene (5 of 7 and 5 of G respectively). A higher frequency of the G allele carriers was observed among patients with negative lymph node status (P = 0.0004). A higher proportion of the patients with positive lymph node status at the time of diagnosis had a combined GSTM1 null/GSTT1 null genotype (P = 0.05). Patients who were homozygous for the deleted GSTM1 allele were found to have a significantly shorter overall survival (P = 0.036). Pharmacogenetics 8:441-447 (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:441 / 447
页数:7
相关论文
共 26 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   PROGNOSTIC-SIGNIFICANCE OF TP53 ALTERATIONS IN BREAST-CARCINOMA [J].
ANDERSEN, TI ;
HOLM, R ;
NESLAND, JM ;
HEIMDAL, KR ;
OTTESTAD, L ;
BORRESEN, AL .
BRITISH JOURNAL OF CANCER, 1993, 68 (03) :540-548
[3]  
ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P13
[4]  
Ban N, 1996, CANCER RES, V56, P3577
[5]  
BROKMOLLER J, 1996, PHARMACOGENETICS, V6, P535
[6]  
CHOW NWI, 1988, J BIOL CHEM, V263, P12797
[7]   GST1 GENE DELETION DETERMINED BY POLYMERASE CHAIN-REACTION [J].
COMSTOCK, KE ;
SANDERSON, BJS ;
CLAFLIN, G ;
HENNER, WD .
NUCLEIC ACIDS RESEARCH, 1990, 18 (12) :3670-3670
[8]   PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP [J].
ELSTON, CW ;
ELLIS, IO .
HISTOPATHOLOGY, 1991, 19 (05) :403-410
[9]  
Gibbs JP, 1996, CANCER RES, V56, P3678
[10]   A PILOT-STUDY OF PI-CLASS GLUTATHIONE-S-TRANSFERASE EXPRESSION IN BREAST-CANCER - CORRELATION WITH ESTROGEN-RECEPTOR EXPRESSION AND PROGNOSIS IN NODE-NEGATIVE BREAST-CANCER [J].
GILBERT, L ;
ELWOOD, LJ ;
MERINO, M ;
MASOOD, S ;
BARNES, R ;
STEINBERG, SM ;
LAZAROUS, DF ;
PIERCE, L ;
DANGELO, T ;
MOSCOW, JA ;
TOWNSEND, AJ ;
COWAN, KH .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :49-58